A General and Efficient Synthesis of 2-Substituted Oxazolopyridines

Abstract

Starting from commercially available halonitropyridines and haloaminopyridines, 2-substituted-oxazolo[5,4-b]pyridines, and 2-aryl-oxazolo[4,5-b]pyridines were synthesized in good yields by using a Cu(I)-mediated cyclization of halopyridylamides as a key step.

copper-catalyzed cyclization - synthesis - heterocycles - oxazolo[5,4-b]pyridines - oxazolo[4,5-b]pyridines

References and Notes

1a Rodriguez AD. Ramirez C. Rodriguez II. Gonzales E. Org. Lett.  1999,  1:  527 

1b Kobayashi J. Madono T. Shigemori H. Tetrahedron Lett.  1995,  36:  5589 

1c Sun LQ. Chen J. Bruce M. Deskus JA. Epperson JR. Takaki K. Johnson G. Iben L. Mahle CD. Ryan E. Xu C. Bioorg. Med. Chem. Lett.  2004,  14:  3799 

1d Paramshivappa R. Kumar PP. Subba Rao PV. Srinivase Rao A. Bioorg. Med. Chem. Lett.  2003,  13:  657 

1e Kumar D. Jacob MR. Reynolds MB. Kerwin SM. Bioorg. Med. Chem.  2002,  10:  3997 

1f Lopez-Tudanca PL. Labeaga L. Innerarity A. Alonso-Cires L. Tapia I. Mosquera R. Orjales A. Bioorg. Med. Chem.  2003,  11:  2709 

2a Yildiz-Oren I. Yalcin I. Aki-Sener E. Ucarturk N. Eur. J. Med. Chem.  2004,  39:  291 

2b Tekiner-Gulbas B. Temiz-Arpaci O. Yildiz I. Aki-Sener E. Yalcin I. SAR QSAR Environ Res.  2006,  17:  121 

2c Clark RL. Pessolano AA. Witzel B. Lanza T. Shen TY. J. Med. Chem.  1978,  21:  1158 

2d Boger DL. Miyauchi H. Du W. Hardouin C. Fecik RA. Cheng H. Hwang I. Hedrick MP. Leung D. Acevedo O. Guimarães CRW. Jorgensen WL. Cravatt BF. J. Med. Chem.  2005,  48:  1849 

2e Deng JZ. McMasters DR. Rabbat PMA. Williams PD. Coburn CA. Yan YW. Kuo LC. Lewis SD. Lucas BJ. Krueger JA. Strulovici B. Vacca JP. Lylea TA. Burgeya CS. Bioorg. Med. Chem. Lett.  2005,  15:  4411 

2f Walczynński K. Zuiderveld OP. Timmerman H. Eur. J. Med. Chem.  2005,  15 

3a Doise M. Dennin F. Blondeau D. Sliwa H. Tetrahedron Lett.  1990,  31:  1155 

3b Doise M. Blondeau D. Sliwa H. Synth. Commun.  1992,  22:  2891 

3c Myllymäki MJ. Koskinen AMP. Tetrahedron Lett.  2007,  48:  2295 

3d Heuser S. Keenanb M. Weichert AG. Tetrahedron Lett.  2005,  46:  9001 

3e Phoon CW. Ng PY. Ting AE. Yeob SL. Sima MM. Bioorg. Med. Chem. Lett.  2001,  11:  1647 

4a Flouzat C. Guillaumet G. Synthesis  1990,  64 

4b Walczynński K. Zuiderveld OP. Timmerman H. Eur. J. Med. Chem.  2005,  40:  15 

4c Garnier E. Blanchard S. Rodriguez I. Jarry C. Léger J.-M. Caubère P. Guillaumet G. Synthesis  2003,  2033 

5 Altenhoff G. Glorius F. Adv. Synth. Catal.  2004,  346:  1661 

6a Ley SV. Thomas AW. Angew. Chem. Int. Ed.  2003,  42:  5400 

6b Kunz K. Scholz U. Ganzer D. Synlett  2003,  2428 

6c Finet JP. Fedorov AY. Combes S. Boyer G. Curr. Org. Chem.  2002,  6:  597 

7 Evindar G. Batey RA. J. Org. Chem.  2006,  71:  1802 

8

Typical Procedure for the Synthesis and Purification of 3a
To a mixture of 2a (2.0 mmol), CuI (0.1 mmol), N,N′-dimethylethylenediamine (0.2 mmol), and K₂CO₃ (4.0 mmol) was added dry toluene (5.0 mL) under a nitrogen atmosphere. The reaction was refluxed for 12 h and then allowed to cool to r.t. The crude mixture was added to 10 mL H₂O and then was extracted by CH₂Cl₂ (2 × 20 mL). The organic layer was dried over anhyd Na₂SO₄ and concentrated in vacuo to give the crude product, which was further purified by flash chromatography over silica gel column with PE-EtOAc (5:1) to give the pure product 3a.

9

Selected Spectral Data
Compound 3a: mp 101-102 ˚C. R _f  = 0.55 (EtOAc-PE, 1:2). IR (KBr): 2913, 1617, 1544 cm^-¹. ^¹H NMR (300 MHz, CDCl₃): δ = 8.38 (dd, J = 5.1, 1.5 Hz, 1 H), 8.34 (d, J = 1.5 Hz, 1 H), 8.34 (d, J = 2.1 Hz, 1 H), 8.10 (dd, J = 7.8, 1.5 Hz, 1 H), 7.55-7.62 (m, 3 H), 7.36-7.41 (m, 1 H). MS (EI):
m/z = 196 [M]⁺. Anal. Calcd for C₁₂H₈N₂O: C, 73.46; H, 4.11; N, 14.28. Found: C, 73.46; H, 4.43; N, 14.18.
Compound 3i: mp 79-81 ˚C. R _f  = 0.38 (EtOAc-PE, 1:2). IR (KBr): 2924, 1602, 1523 cm^-¹. ^¹H NMR (300 MHz, CDCl₃): δ = 8.35 (dd, J = 4.2, 1.5 Hz, 1 H), 8.21 (dd, J = 7.8, 1.5 Hz, 1 H), 8.12 (dd, J = 7.8, 1.5 Hz, 1 H), 7.53-7.56 (m, 1 H), 7.32-7.37 (m, 1 H), 7.10-7.16 (m, 2 H), 4.05 (s, 3 H). MS (EI): m/z = 226 [M]⁺. Anal. Calcd for C₁₃H₁₀N₂O₂: C, 69.02; H, 4.46; N, 12.38. Found: C, 68.67; H, 4.34; N, 12.38.
Compound 3k: mp 172-174 ˚C. R _f  = 0.42 (EtOAc-PE, 1:2). IR (KBr): 1496, 1620, 1223 cm^-¹. ^¹H NMR (300 MHz, CDCl₃): δ = 8.34 (dd, J = 4.5, 1.5 Hz, 1 H), 8.05 (dd, J = 7.8, 1.5 Hz, 1 H), 7.54 (s, 2 H), 7.33-7.37 (m, 1 H), 4.04 (s, 9 H). MS (EI): m/z = 286 [M]⁺. Anal. Calcd for C₁₅H₁₄N₂O₄: C, 62.93; H, 4.93; N, 9.79; Found: C, 63.12; H, 4.74; N, 9.78.
Compound 6a: mp 163-164 ˚C. R _f  = 0.38 (EtOAc-PE, 1:2). IR (KBr): 2920, 1670, 1580 cm^-¹. ^¹H NMR (300 MHz, CDCl₃): δ = 8.56 (s, 1 H), 8.46 (dd, J = 1.5, 7.2 Hz, 2 H), 7.81 (s, 1 H), 7.75-7.65 (m, 3 H), 2.65 (s, 3 H). ^¹³C NMR (75 MHz, CDCl₃): δ = 165.1, 154.4, 147.3, 132.3, 130.6, 129.0, 128.0, 126.7, 118.5, 18.9. ESI-MS: m/z = 211 [M⁺ + 1]. Anal. Calcd for C₁₃H₁₀N₂O: C, 74.27; H, 4.79; N, 13.33. Found: C, 74.05; H, 4.77; N, 13.28.
Compound 6b: mp 165-167 ˚C. R _f  = 0.35 (EtOAc-PE, 1:2). IR (KBr): 2918, 1620, 1550 cm^-¹.^¹H NMR (300 MHz, CDCl₃): δ = 8.57 (s, 1 H), 8.32 (d, J = 8.4 Hz, 2 H), 8.01 (d, J = 8.3 Hz, 2 H), 7.84 (s, 1 H), 3.95 (s, 1 H), 2.64 (s, 3 H). ESI-MS: m/z = 241 [M⁺ + 1]. Anal. Calcd for C₁₃H₁₀N₂O: C, 69.99; H, 5.03; N, 11.66. Found: C, 69.78; H, 4.98; N, 11.69.
Compound 6c: mp 193-194 ˚C. R _f  = 0.32 (EtOAc-PE, 1:2). IR (KBr): 2918, 1610, 1560 cm^-¹.^¹H NMR (300 MHz, CDCl₃): δ = 8.59 (s, 1 H), 8.16 (d, J = 8.7 Hz, 2 H), 8.04 (d, J = 8.1 Hz, 2 H), 7.84 (s, 1 H), 2.64 (s, 3 H). ^¹³C NMR (75 Hz, CDCl₃): δ = 164.3, 154.2, 147.7, 143.3, 138.4, 130.9, 129.3, 126.2, 118.6, 99.5, 18.9. ESI-MS: m/z = 337 [M⁺ + 1]. Anal. Calcd for C₁₃H₉IN₂O: C, 46.45; H, 2.70, N, 8.33. Found: C, 46.53; H, 2.75; N, 8.40.